Collective Family Office LLC Cuts Holdings in Novo Nordisk A/S (NYSE:NVO)

Collective Family Office LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 61.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 2,499 shares of the company’s stock after selling 3,917 shares during the quarter. Collective Family Office LLC’s holdings in Novo Nordisk A/S were worth $215,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of NVO. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S during the second quarter valued at about $25,000. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $28,000. Abound Wealth Management boosted its holdings in Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the period. Capital Performance Advisors LLP purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Finally, Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at $48,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent research reports. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. Finally, BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Trading Up 2.3 %

Novo Nordisk A/S stock traded up $1.95 during mid-day trading on Wednesday, reaching $85.29. 3,861,972 shares of the company traded hands, compared to its average volume of 6,442,661. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 52-week low of $81.50 and a 52-week high of $148.15. The firm has a market capitalization of $382.74 billion, a price-to-earnings ratio of 27.60, a P/E/G ratio of 1.37 and a beta of 0.45. The firm’s 50 day moving average price is $101.94 and its 200 day moving average price is $120.27.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.